Specialty HUBs

Specialty Hub Services News Roundup: May 2023

Posted on by John Santilli

Patient access remains the key link between pharmaceutical companies and patients with specialty therapeutics. Hub Services providers remain at the forefront of this activity.

Conduent Incorporated announced the launch of the IntelliHealth module for healthcare provider engagement. This new module is an end-to-end solution to help pharma organizations improve access to, and increase engagement with, healthcare professionals to drive focused pharmaceutical sales and marketing. IntelliHealth enables pharma organizations to power faster and more effective product commercialization with advanced analytics, omnichannel communication and experienced sales professionals and medical science liaisons. The robust platform delivers highly flexible hybrid engagement models that enable pharma organizations to reduce risk, manage costs and gain competitive advantages while driving ROI across the full life cycle of a drug therapy.

QHP Capital, L.P., the management company for NovaQuest Private Equity, announced an investment in COPILOT Provider Support Services, LLC (COPILOT), a hub services platform. Since its beginning in 2010, COPILOT has helped healthcare providers and patients access customized healthcare solutions for quicker access to therapy through partnerships with pharmaceutical companies. COPILOT has the infrastructure to support both large volume products and small population rare disorder treatments from launch onward and prides itself in being a fast, flexible and accurate system for all stakeholders involved.

EVERSANA  initiated a number of activities recently:

  • Shorla Oncology (Shorla), a U.S.-Ireland pharmaceutical company, and EVERSANA® announced the commercial launch of the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
  • EVERSANA announced a partnership with ChemoMouthpiece, LLCto support the launch and commercialization of its medical device, the Chemo Mouthpiece™,  to assist oncology patients across the United States. 
  • Xspray Pharma AB signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company’s first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). While maintaining financial and strategic control, Xspray Pharma will grant EVERSANA exclusive commercialization access to support its Dasynoc launch, aimed at the second half of 2023.
  • Yaral Pharma, the United States generics subsidiary of IBSA (Institut Biochimique SA), announced its expanding partnership with EVERSANA® as its key commercialization partner to support the expansion of its portfolio of pain and endocrinology products in the US. EVERSANA will provide a full range of services including, but not limited to, third-party logistics (3PL) and critical operations support to ensure best-in-class customer service for Yaral Pharma.

OptimizeRx Corp. announced a multi-million-dollar, three-year agreement with a leading Hub services company that will leverage OptimizeRx technology to accelerate patient access for its life sciences brands through digitization of disparate processes. The patient services provider will license the electronic Hub technology which was introduced to the OptimizeRx suite of solutions through the EvinceMed acquisition in 2022. The engagement is focused on determining drug eligibility and affordability and will help accelerate access to coverage and affordability information for pharma-sponsored patient support programs.

Precision Value & Health acquired Makara Health, a UK-based international healthcare communications agency. The move will expand Precision’s European footprint and reinforce the company’s market growth position with its core capabilities in Europe. Founded in 2013, Makara has capabilities in learning and development, medical and patient education, PR and brand promotion, offering its diverse roster of healthcare client companies high-quality, strategic, scientifically robust programs, as well as creative delivery solutions. With this acquisition, Makara becomes part of the Precision Value & Health team. The Makara team will work closely with PRECISIONscientia, an agency dedicated to delivering medical and scientific communications that expertly interpret and translate the science of medicine.

 

Takeaway: AMI’s annual Specialty Hub Service Providers Report provides comprehensive business intelligence on more than 70 companies